Condensed pyrimidines
    1.
    发明授权
    Condensed pyrimidines 失效
    浓缩嘧啶

    公开(公告)号:US4495189A

    公开(公告)日:1985-01-22

    申请号:US364753

    申请日:1982-04-02

    IPC分类号: C07D471/04 A61K31/505

    CPC分类号: C07D471/04

    摘要: New compounds of the following formula are disclosed:1,6-dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)-pyrimidine;1,6-dimethyl-3-(N-tertiary-butyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-2-phenethyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-[N-(3,3-diphenyl-propyl)-carbamoyl]-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-phenyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine; and1,6-dimethyl-3-(N-methyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine, as well as pharmaceutical compositions containing these compounds and a method of inhibiting thrombocyte aggregation in mammals employing a pharmaceutically effective amount of at least one of these compounds.

    摘要翻译: 公开了下式的新化合物:1,6-二甲基-3-氨基甲酰基-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a) - 吡啶亚胺; 1,6-二甲基-3-(N-叔丁基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶; 1,1-二甲基-3-(N-2-苯乙基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-哒嗪(1,2-a)嘧啶; 1,6-二甲基-3- [N-(3,3-二苯基 - 丙基) - 氨基甲酰基] -4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶 ; 1,6-二甲基-3-(N-苯基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶; 和1,6-二甲基-3-(N-甲基 - 氨基甲酰基)-4-氧代-1,6,7,8-四氢-4H-吡啶并(1,2-a)嘧啶,以及含有这些的药物组合物 化合物和使用药学上有效量的这些化合物中的至少一种来抑制哺乳动物血小板聚集的方法。

    Boric anhydrides of
6-fluoro-7-chloro-1-methylamino-4-oxo-1,4-dihydro-quinoline-3-carboxylic
acid
    5.
    发明授权
    Boric anhydrides of 6-fluoro-7-chloro-1-methylamino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 失效
    6-氟-7-氯-1-甲基氨基-4-氧代-1,4-二氢 - 喹啉-3-羧酸的硼酸酐

    公开(公告)号:US4806645A

    公开(公告)日:1989-02-21

    申请号:US105295

    申请日:1987-08-07

    CPC分类号: C07F5/04

    摘要: The invention relates to new 6-fluoro-7-chloro-1-methylamino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid/boric acid anhydrides of the general Formula I ##STR1## (wherein R and R.sup.1 stand for halogen; an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen; or an aromatic acyloxy group comprising 7-11 carbon atoms).The new compounds of the general Formula I are valuable intermediates useful in the preparation of the antibacterial agent 6-fluoro-1-methylamino-7-(4-methyl-piperazino)-4-oxo-1,4-dihydro-quinoline-3- carboxylic acid.The new compounds of the general Formula I may be prepared by reacting a compound of the Formula II ##STR2## or a compound of the general Formula III ##STR3## (wherein R.sup.2 stands for alkyl comprising 1-4 carbon atoms) with hydrogen fluoro borate of the Formula IVHBF.sub.4 /IV/or a borone trihalide of the general Formula VBX.sub.3 /V/(wherein X stands for fluorine, chlorine or bromine) or a complex thereof formed with an ether or a borone derivative of the general Formula VI ##STR4## (wherein R.sup.3, R.sup.4 and R.sup.5 stand for alkyl comprising 1-5 carbon atoms and optionally substituted by halogen or aryl comprising 6-10 carbon atoms).

    摘要翻译: PCT No. PCT / HU86 / 00066 Sec。 371日期1987年8月7日 102(e)日期1987年8月7日PCT申请日1986年12月9日PCT公布。 公开号WO87 / 03594 日期:1987年6月18日本发明涉及通式I的新的6-氟-7-氯-1-甲基氨基-4-氧代-1,4-二氢 - 喹啉-3-羧酸/硼酸酐, 图像(I)(其中R和R1代表卤素;包含2-6个碳原子并任选被卤素取代的脂族酰氧基;或包含7-11个碳原子的芳族酰氧基)。 通式I的新化合物是可用于制备抗菌剂6-氟-1-甲基氨基-7-(4-甲基 - 哌嗪子基)-4-氧代-1,4-二氢 - 喹啉线衍生物的有价值的中间体, 3-羧酸。 通式I的新化合物可以通过使式II的化合物(II)或通式III的化合物(III)(其中R 2代表包含1-4个碳原子的烷基) 原子)与式IV的氢氟硼酸盐HBF 4 / IV /或通式V BX 3 / V /(其中X表示氟,氯或溴)的三卤化硼硼烷或其与醚或硼烷衍生物形成的络合物 通式VI(VI)(其中R 3,R 4和R 5代表包含1-5个碳原子并且任选地被卤素或包含6-10个碳原子的芳基取代的烷基)。

    Norfloxacin intermediate
    6.
    发明授权
    Norfloxacin intermediate 失效
    诺氟沙星中间体

    公开(公告)号:US4803274A

    公开(公告)日:1989-02-07

    申请号:US105298

    申请日:1987-08-07

    CPC分类号: C07F5/04

    摘要: The invention relates to a process for the preparation of compounds of the Formula I ##STR1## (wherein R and R.sup.1 stand for an aliphatic acyloxy group comprising 2-5 carbon atoms and optionally substituted by halogen or for an aromatic acyloxy group comprising 7-11 carbon atoms), which comprises reacting a compound of the general Formula II ##STR2## (wherein R.sup.2 stands for hydrogen or alkyl comprising 1-4 carbon atoms) with a boron derivative of the Formula III ##STR3## (wherein R.sup.3, R.sup.4 and R.sup.5 stand for an alkyl group comprising 1-4 carbon atoms and optionally substituted by halogen or for an aryl group comprising 6-10 carbon atoms).The new compounds of the general Formula I are useful pharmaceutical intermediates.

    摘要翻译: PCT No.PCT / HU86 / 00068 Sec。 371日期1987年8月7日 102(e)日期1987年8月7日PCT申请日1986年12月9日PCT公布。 第WO87 / 03595号公报 日本1987年6月18日。本发明涉及制备式I化合物(I)的方法(其中R和R 1代表包含2-5个碳原子并任选被卤素取代的脂族酰氧基 或包含7-11个碳原子的芳族酰氧基),其包括使通式II的化合物(II)(其中R 2表示氢或包含1-4个碳原子的烷基)与式 式III(III)(其中R3,R4和R5代表含有1-4个碳原子的烷基,任选被卤素取代或含有6-10个碳原子的芳基)。 通式I的新化合物是有用的药物中间体。

    Process for the preparation of quinoline carboxylic acids
    9.
    发明授权
    Process for the preparation of quinoline carboxylic acids 失效
    制备喹啉羧酸的方法

    公开(公告)号:US5300644A

    公开(公告)日:1994-04-05

    申请号:US756345

    申请日:1991-09-06

    CPC分类号: C07D215/56

    摘要: The invention relates to a new process for the preparation of compounds of the general Formula I ##STR1## wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group and pharmaceutically acceptable salts thereof which comprises reacting a compound of the general Formula II ##STR2## wherein R.sup.1 and R.sup.2 stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms and optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms with a piperazine derivative of the general Formula III ##STR3## wherein R.sup.3 stands for hydrogen, methyl or ethyl or a salt thereof and subjecting the compound of the general Formula IV ##STR4## thus obtained wherein R, R.sup.1 and R.sup.2 are as stated above to hydrolysis after or without isolation and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the general Formula I are known antibacterial agents.

    摘要翻译: 本发明涉及制备通式Ⅰ(I)化合物的新方法,其中R代表哌嗪基,4-甲基 - 哌嗪基或4-乙基 - 哌嗪基及其药物上可接受的盐,其包括使 通式II的化合物(II)其中R1和R2代表卤素,含2至6个碳原子的脂族酰氧基并任选被卤素取代,或含有7至11个碳原子的芳族酰氧基与 通式III的哌嗪衍生物(III)其中R3代表氢,甲基或乙基或其盐,并对由此得到的通式IV的化合物(IV)进行反应,其中R 1,R 2和R 2 如上所述,在分离后或不分离时进行水解,如果需要,将由此获得的通式I的化合物转化为其盐或使其与其盐相同。 通式I的化合物是已知的抗菌剂。

    Baron chelates of quinoline carboxylic acids
    10.
    发明授权
    Baron chelates of quinoline carboxylic acids 失效
    喹啉羧酸的巴伦酸

    公开(公告)号:US5091530A

    公开(公告)日:1992-02-25

    申请号:US290105

    申请日:1988-11-23

    CPC分类号: C07D215/56

    摘要: The invention relates to a new process for the preparation of compounds of the general Formula I ##STR1## /wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group/ and pharmaceutically acceptable salts thereof which comprises reacting a compound of the general Formula II ##STR2## /wherein R.sup.1 and R.sup.2 stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms and optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms/ with a piperazine derivative of the general Formula ##STR3## /wherein R.sup.3 stands for hydrogen, methyl or ethyl/ or a salt thereof and subjecting the compound of the general Formula IV ##STR4## thus obtained /wherein R, R.sup.1 and R.sup.2 are as stated above/ to hydrolysis after or without isolation and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the general Formula I are known antibacterial agents.The advantage of the present invention is that it makes the desired compounds of the general Formula I available in a simple manner, with high yields and in a short reaction time.

    摘要翻译: PCT No.PCT / HU88 / 00019 Sec。 371日期1988年11月23日第 102(e)日期1988年11月23日PCT提交1988年4月8日PCT公布。 公开号WO88 / 07993 1988年10月20日的日期。本发明涉及制备通式I化合物的新方法,其中R代表哌嗪基,4-甲基 - 哌嗪基或4-乙基 - 哌嗪基/ 或其药学上可接受的盐,其包括使通式II的化合物其中R 1和R 2表示卤素,含有2至6个碳原子的脂族酰氧基并且任选被卤素取代,或 含有7〜11个碳原子的芳香族酰氧基/通式为其中R 3代表氢,甲基或乙基/或其盐,并通式IV的化合物 / IV /由此获得的/其中R,R 1和R 2如上所述/在分离后或不分离下进行水解,如果需要,将所得通式I的化合物转化为其盐或使其与其盐相同。 通式I的化合物是已知的抗菌剂。 本发明的优点在于使得所需的通式Ⅰ化合物以简单的方式得到,产率高,反应时间短。